Erythema Infectious: Causes, Symptoms & Treatment
“`html
RSV Vaccine Approved for Older Adults: A Breakthrough in Respiratory Protection
Table of Contents
Understanding RSV: More Than Just a Common Cold
Respiratory Syncytial Virus (RSV) is often dismissed as a childhood illness, but it poses a important threat to older adults. While most people recover from RSV with symptoms similar to a common cold,the virus can lead to serious complications like pneumonia and bronchiolitis,particularly in those with weakened immune systems or underlying heart or lung conditions. before the availability of vaccines, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths among adults 65 years and older annually in the United States.
The virus spreads through respiratory droplets produced when an infected person coughs or sneezes. Symptoms typically appear 4-6 days after infection and include a runny nose, decreased appetite, cough, sneezing, fever, and wheezing. For older adults, these symptoms can quickly escalate, requiring hospitalization and possibly leading to long-term health consequences.
The Breakthrough: Arexvy and Abrysvo – How They Work
The FDA’s approval of Arexvy (GSK) on May 3, 2023, and Abrysvo (Pfizer) on August 21, 2023, marks a pivotal moment in RSV prevention. Both vaccines utilize different technologies to stimulate an immune response. Arexvy is a recombinant subunit vaccine containing a stabilized prefusion F protein, while Abrysvo also uses a prefusion F protein but employs a different manufacturing process. The F protein is a key component of the RSV virus that allows it to enter cells; by targeting this protein, the vaccines train the immune system to recognize and neutralize the virus.
clinical trials demonstrated the efficacy of both vaccines. The Arexvy trial, involving nearly 18,000 adults, showed approximately 82.6% efficacy in preventing RSV-associated lower respiratory tract disease (LRTD) with at least one symptom. Abrysvo’s clinical trials showed approximately 85.7% efficacy against severe LRTD. It’s important to note that these vaccines are designed to prevent illness, not necessarily to eliminate infection entirely.
Who Should Get Vaccinated? And When?
the FDA approved both vaccines for adults aged 60 years and older.Though, the Centers for Disease Control and Prevention (CDC) and its Advisory Committee on Immunization Practices (ACIP) will provide specific recommendations regarding who *should* receive the vaccine. These recommendations will likely consider factors such as individual health status,risk of exposure,and potential vaccine side effects.
the timing of vaccination is also crucial. The goal is to administer the vaccine before the start of the RSV season, which typically begins in the fall and peaks during the winter months. The ACIP is expected to recommend a one-time dose for most adults, although further boosters may be considered in the future